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Abstract
Background: Patients who have had initial curative intent therapy for non-metastatic soft tissue sarcoma, and who
subsequently relapse at the initial site without evidence of metastatic disease, have various options regarding local treatment.
The treatment options available will be determined by the extent of relapse, previous therapy rendered, and patient
characteristics. We reported on a series of 31 patients treated initially with only surgery for extremity/trunkal high-grade soft
tissue sarcoma and then seen for recurrence at our institution between 1980 and 1999. Local re-treatment consisted
of combined modality therapy, most often aggressive surgical debulking/resection and irradiation, in an effort to reduce
the need for amputation and, where anatomically allowable, to maintain a functional limb. We report our results in
re-establishing local control, subsequent survival, and complication rates.
Methods: Thirty-one patients with locally recurrent, non-metastatic high-grade soft tissue sarcoma, (excluding extra-
abdominal desmoid) were retrospectively reviewed to determine local control, survival, and complication rates associated
with the relapsed disease. All patients had multimodality re-treatment most often utilizing aggressive surgical debulking and
irradiation. The irradiation consisted of either external beam alone, brachytherapy alone, or a combination of external beam
and brachytherapy. Nine patients also received multi-agent, multi-cycle chemotherapy using various regimens. In addition,
the impact of surgical margin at the time of re-resection (gross versus microscopic disease), radiation treatment type, total
radiation dose delivered, size of relapse, histological sub-type, sex and age, were evaluated to determine if they had any
impact on the re-establishment of local control and subsequent survival.
Results: Local control was re-established in 25 of 31 (80.6%) patients. Two additional patients with isolated local relapse
after irradiation were salvaged with amputation and remain NED at last follow-up. With these patients a total of 27/31 (87%)
are now with local control. At last follow-up, which ranged from 23 to 192 months, 23 of 31 (74%) remained alive. Of the
eight patients who have died, four had evidence of local and distant failure. Two additional patients died of distant failure
while the treated sites remained in local control and two patients, both NED, died of intracurrent processes. Follow-up for
those patients who had re-established local control has ranged from 23 to 192 months (median¼60.5 months). Time to
local failure following re-treatment ranged between 3 and 72 months following re-treatment (median¼12 months). Five
patients had significant treatment related complications. Included are two patients in which amputation was required due to
local recurrences. Two patients developed a soft tissue necrosis and one patient had a wound healing problem that resolved
with conservative management. No statistical significance in the development of local control could be found based on
surgical margin status, total dose of irradiation (greater or less than 60Gy), size of recurrence (greater than 5cm),
histological sub-type, sex, or age (greater than 50 years). There was a trend for negative impact for those patients receiving
only external beam irradiation.
Conclusion: Selective locally recurrent, non-metastatic soft tissue sarcoma of the extremity/trunkal regions should still be
considered eligible for aggressive limb-sparing therapy. Our experience suggests that a majority of patients re-establish local
control following aggressive surgical resection/debulking and irradiation and this appears to be durable in its nature. The role
of chemotherapy in this group of patients remains investigational. In a surprising finding, one patient re-relapsed in the
re-treatment site at 72 months, thus justifying continued strict surveillance not only in the primary site but also for
subsequent metastatic disease.
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The treatment of soft tissue sarcomas continues to
undergo study as new combined modality strategies
are designed to improve the ability to establish
limb salvage and reduce the chance of metastatic
spread.
1–4 While there has been impressive local
control data using these strategies, there remains
between 10 and 20% of patients in whom initial local
control is not established.
The treatment options available to these patients
are based not only on local disease issues, but
whether or not metastatic disease is present. The
number of patients in whom locally recurrent non-
metastatic soft tissue sarcoma is present, has not
been well-defined in the literature although it has
been reported in up to half of those who locally
relapse.
5,6
In an era where 80–90% of local control rates are
reported using combined modality therapy for initial
treatment, these locally relapsed patients are unique
in that they may benefit from aggressive local
re-treatment and may enjoy long-term disease-free
survival.
It has been reported that certain prognostic factors
such as size (greater than 5cm), status of surgical
margin, histological sub-type, age, and total dose of
irradiation may also impact on local control and
survival.
7–10
The objective of this retrospective review was to
report on local control, overall survival and compli-
cation rates in those patients receiving re-treatment
using combined modality therapy. Additionally, we
reviewed the relationship of the status of surgical
margin at the time of re-treatment, type of radiation
used, total dose of radiation, size of relapse,
histological sub-type, sex and age, to determine if
any of these factors impacted on local control or
overall survival.
Methods and materials
A retrospective review of all patients seen in the
Department of Radiation Oncology at the Karmanos
Cancer Institute/Detroit Medical Center from 1980
to 1999, who presented with recurrent soft tissue
sarcoma, was undertaken. One hundred and two
patients were identified, of which 31 had biopsy-
proven high grade, locally relapsed soft tissue
sarcoma of an extremity/trunkal site without evi-
dence of metastatic disease. Patient characteristics
are listed in Table 1. There were 17 males and 14
females; ages ranged from 18 to 88 years at the time
of initial diagnosis. Sites included lower extremity
(n¼17), trunkal (n¼10), and upper extremity
(n¼4).
The most frequently noted histology was liposar-
coma (n¼8) followed by malignant fibrohistio-
cytoma (MFH; n¼7), leiomyosarcoma (n¼6), and
synovial sarcoma (n¼3). Tumor characteristics are
noted in Table 2.
All patients had a previous history of surgical
extirpation. Time to initial relapse from initial
surgery ranged from 2 to 190 months (median¼36
months). Twelve patients had a history of multiple
resections for local relapse prior to treatment with
combined modalities. At the time of last surgery, the
surgical margins were microscopically positive or
close (within 3mm) in 25 patients and grossly
positive in six patients. These were reviewed by one
of the authors (D.R.L.).
Irradiation was used in all patients and inclu-
ded external beam radiation alone (n¼16; dose
range 45–68Gy), brachytherapy alone (n¼4; two
patients received neutron brachytherapy utilizing
californium-252, two patients received high-dose
rate remote afterloading using iridium-192), and 11
patients who had a combination of external beam
irradiation and brachytherapy.
Table 2. Tumor characteristics
Liposarcoma n¼8
MFH n¼7
Leiomyosarcoma n¼6
All others n¼10
Site
Lower extremity n¼17
Trunkal n¼10
Upper extremity n¼4
Radiation treatment
schema
External beam n¼16
Brachytherapy n¼4
External beam and
brachytherapy
n¼11
Surgical Margins
(last surgery)
Microscopic positive or
within 5mm
n¼25
Grossly positive n¼6
Size of relapse
 5cm n¼19
 5cm n¼12
Table 1. Patient characteristics
Male n¼17
Female n¼14
Ages 18–88 years
Median n¼53 years
Time to re-treatment 2–190 months
Median¼36 months
Follow up 23–192 months
Median¼60.5 months
Local control 25/31 (80.6%)
Local failure time from
re-treatment to
local failure
6/31 (19.4%): 3–72 months
(Median¼12 months)
58 J. Fontanesi et al.Prior to 1994 there was no consensus depart-
mental policy on what type of treatment or total dose
to be used in this set of patients.
Beginning in 1994, high dose rate brachytherapy
(HDR) was used as a ‘boost’ prior to initiation of
external beam irradiation in patients with relapsed
soft tissue sarcoma. The planned brachytherapy dose
was to be 350 cGy to a 0.5-cm margin around
surgically placed clips for Ir-192 HDR. For those
treated with Cf-252, a neutron-emitting brachyther-
apy source, twice daily doses of 100 NcGy were
delivered to the same volume as the HDR-treated
patients. In combined cases, the HDR brachytherapy
was immediately followed by initiation of external
beam irradiation. The plan for this external beam
was to deliver 200 cGy per day to a total dose of
50Gy. The treatment volume ranged between 3 and
5cm around the surgically placed clips.
For those receiving only brachytherapy with
Cf-252 the total dose was between 7 and 9 NGy,
again delivered twice daily and was used for patients
with small lesions with microscopically positive
surgical margins. We used an RBE of 4.5 when
calculating neutron dose.
No patient has been lost to follow-up. Follow-up
has ranged from 23 to 192 months, with a median of
60.5 months. This follow-up was started from the
time of completion of the irradiation during the
re-treatment.
Results
Local control in the relapsed area was established in
25 of 31 (80.6%) patients. Follow-up for these
patients has ranged from 23 to 192 months
(median¼60.5 months).
Six patients developed local failure in the
re-treatment area. No patient treated with brachy-
therapy alone failed, while two of 11 (18%) with
combined external beam and brachytherapy had
local failure. Four of sixteen (25%) treated with
external beam irradiation alone developed local
failure. Recurrence occurred from 3 to 72 months
following completion of irradiation. The median
time from re-treatment to relapse was 12 months.
One patient had local failure at 72 months. Two of
six patients were salvaged and both remain NED
following surgical amputation. Time to death ranged
from 13 to 121 months post radiation.
No patient treated with gross residual disease has
locally failed; however, two have died of distant
disease. All local failures have occurred in those
treated for microscopically positive/close margins.
Tumor characteristics of those patients with local
failure are noted in Table 3.
There was no significance identified using uni-
variate analysis for status of margin at the time of last
surgery, the size of relapse, histology, total dose of
radiation used, sex or age. There was a slight trend
for improved local control in those patients receiving
brachytherapy as part of their irradiation.
Survival
At the time of last follow-up, 23 of 31 (74%) patients
remained alive. Twenty-one have been disease free
since completion of radiation. Two have had surgical
salvage following local failure and remain NED at
last follow-up. Follow-up for these patients ranges
from 23 to 192 months (median¼60 months).
Eight patients have died. Four have died with a
combination of local and distant failure and two have
died of distant failure without local failure. Two
patients have died of intracurrent disease, each had
local control and no evidence of metastatic disease at
the time of their death at 3 and 20 months following
completion of irradiation. Those with local/distant
failure died between 13 and 121 months following
completion of irradiation. Univariate nor multi-
variate analysis could establish significance for any
of the study factors as an independent reason
influencing survival.
Complications
As expected, most patients developed acute tissue
reactions following irradiation. However, five of 31
(16%) developed significant complications. Two
patients developed soft tissue necrosis. In one
patient, 121 months had elapsed between initial
Table 3. Patients characteristics of local failure
Patient Age Sex Size at
relapse
Site Histology Time to
initial
relapse
Surgical
margins
Time to
relapse
Status
15 4 8 Trunkal MFH 12 M 12 # LF/DD
23 0 9 Upper extremity Synovial sarcoma 60 M 12 # LF/DD
34 0 8 Upper extremity MFH 30 M 12 # LF/ DD
47 5 8 Lower extremity RMS 96 M 8 # LF/DD
56 7 8 Upper extremity Leiomyosarcoma 12 M 3 NED following
surgical salvage
66 0 8 Lower extremity Synovial sarcoma 6 M 72 NED following
surgical salvage
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only external beam irradiation (60Gy/30 fractions).
The treatment area was involved in trauma that
resulted in a non-healing wound that required
surgical intervention following failure of conservative
healing measures.
The second patient who developed soft tissue
necrosis received surgery, external beam irradiation
and brachytherapy along with multiagent, multicycle
chemotherapy at the time of re-treatment. This
upper extremity site developed a wound dehiscence
that also had positive bacterial cultures. This
eventually healed with conservative measures. One
patient developed a wound dehiscence following
combined brachytherapy/external beam irradiation.
This healed with conservative management within 6
weeks of development.
Two patients had amputation following local
relapse. These patients had significant pain and/or
functional loss of the affected areas. Following
surgery, there was noted significant pain improve-
ment and both remain NED.
Discussion
The treatment of localized non-metastatic soft tissue
sarcoma continues to undergo refinements designed
to maximize local control and improve the ability
to maintain function where possible. With most
modern series reporting 80–90% local control rates,
5-year survival rates continue to range from 55 to
65%. Thus, while local control is excellent with
modern therapy, investigations on how to decrease
distant failure and improve overall survival has been
the focus of much activity.
11–13 Since many patients
receive multi-modality therapy, for those few with
local relapse without evidence of metastatic disease,
treatment options may be limited. Previous irradia-
tion, limb-salvage surgery and chemotherapy can all
affect potential new therapy that may be used.
Those who present with localized disease and who
subsequently relapsed locally without evidence clini-
cally or radiographically of distant failure, make up a
relatively small number of patients. In fact, it has
been reported that about 50% of patients with high
grade soft tissue sarcomas who locally relapsed, will
eventually develop metastatic disease within 24
months.
21 During the past 20 years, surgical treat-
ment preferences have changed from amputation
to limb salvage in conjunction with multi-modality
treatments. Thus, there are an ever-increasing num-
ber of patients who may fit this unique category.
There are few series that report on the outcome of
patients with local non-metastatic relapsed soft tissue
sarcoma. Lewis et al. and Stojadinovic et al. reported
on the Memorial Sloan-Kettering data for non-
metastatic locally relapsed soft tissue sarcomas and
found no survival difference from those who were
referred at primary disease presentation.
14,15
An important note to these two series was the fact
that recurrences greater than 5cm, high-grade
tumors, positive re-resection margins, and specific
histologies, namely leiomyosarcoma and fibrosar-
coma, predicted for poorer survival rates. This is
different from the presented series in which neither
histology, surgical margin, nor size were predictors of
local control or survival. In fact, no patient with gross
residual surgical margins has failed locally in the
present series. In addition, it must be noted that all
tumors in the present series were high grade. It is also
important to know that each patient had high grade
recurrent soft tissue sarcoma within 5mm of the
surgical margin. Thus, the 80% local control rate is
encouraging as is the 74% survival rate.
There has been little information on the
re-treatment of patients who are radiation naive at
the time of local relapse. There have been limited
reports of local control and survival following
re-irradiation either alone or in conjunction with
limb-salvage procedures and/or amputation. A real
question is if radiation is really required, especially in
those cases who undergo amputation and/or limb-
salvage procedures with wide margins of resection. A
recent series by Baldini et al. suggests that following
adequate initial surgical resection with margins of
resection playing the key indicator (100% local
control for margins greater than 1cm compared to
87% for those less than or equal to 1cm) irradiation
may not be necessary. The series also reported that
tumor grade, size, site, nor depth had negative
impact on local control.
16 This concept has also
been reported by others.
17
Our report of local control of 80% is similar to
many series detailing initial presentation and treat-
ment. Statistical analyses of our series found a trend
for increasing local failure in those patients receiving
only external beam irradiation for close surgical
margins, although numbers receiving brachytherapy
alone or in conjunction with brachytherapy may be
too small to be able to accurately predict this fact.
It may be that in these patients with relapsed local
disease, that the overall time which was required to
deliver external beam irradiation, may play an
important part in the eventual ability to maintain
local control.
We are also encouraged by the low incidence of
treatment-related complications although if we
include the patients who required amputation for
local failure as a complication, this is still an
acceptable 16%.
This retrospective review is narrow in its focus:
locally recurrent, radiation-naive and non-metastatic
soft tissue sarcoma. Despite this focus, it is encour-
aging that these patients have a substantial capacity
for long-term, disease-free intervals following aggres-
sive multi-modality therapy. We have not had an
unusual rate of patients developing metastatic
disease as has been previously reported in patients
60 J. Fontanesi et al.with high grade soft tissue sarcoma at the time of
initial presentation. We also could not demonstrate
that surgical margin status, time to local relapse,
radiation dose, nor size were negatively predictive for
poor outcomes. The only trend for poor local control
was with the use of external beam irradiation alone in
those patients with close margins.
Conclusion
Based on this experience, we continue to recom-
mend the aggressive surgical resection followed by
irradiation using brachytherapy alone (for lesions less
than 5cm in size) or in conjunction with external
beam irradiation for larger lesions. The role of
chemotherapy should be reserved for those patients
in a protocol setting since its use has yet to be fully
identified and defined.
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